Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Autoimmune Disease
- Main trialPhase 1
- “The primary objective of the study is to evaluate the safety and tolerability of ALT-01 in healthy participants”In the company’s words, NCT07865442 on ClinicalTrials.gov
Other drugs for Autoimmune Disease
- RilzabrutinibSanofi · Phase 3
- IMU-838Immunic AG · Phase 3
- TirzepatideEli Lilly · Phase 3
- Descartes-08Cartesian Therapeutics · Phase 3
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- GefurulimabAlexion Pharmaceuticals, Inc. · Phase 3
Coming up1
- 30 Sep 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 30 Sep 2027 | First in Human Study of ALT-01 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026